Abstract
Iodixanol (visipaque, 320 mgI/ml) was compared with iopamidol (Solutrast, 370 mfI/ml) in a double-blind, randomized, parallel group, intravenous DSA phase-III trial for evaluation of safety and efficacy. A total of 117 patients received iodixanol (n = 60) or iopamidol (n = 57). Diagnostic efficacy was evaluated using categoric and visual analogue scales. Discomfort and adverse evenets were recorded. A total of 39 patients collected urine up to 72 h after the examination for analysis. Diagnostic efficacy and radiographic density were similar in both groups. Discomfort was milder with iodixanol. The difference between the frequency of adverse events between both groups (iodixanol = 7, iopamidol = 2) was without statistical significance. Creatinine clearance was slightly more affected by iodixanol, whereas the increase in renal excretion ofN-acetyl-beta-glucosaminidase (NAG) in the first 24 h collection period after the examination was significantly higher (p < 0.01) with iopamidol. Iodixanol was of equal diagnostic efficacy compared with iopamidol despite its reduced iodine content. Both contrast media are well suited for IV DSA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ford KK, Newman GE, Dunnick NR (1984) The optimal contrast material for digital subtraction angiography of renal arteries: ionic or nonionic? Invest Radiol 19: 244–246
Jynge P, Holten T, Øksendal AN (1993) Sodium-calcium balance and cardiac function wih isotonic iodixanol. An experimental study in the isolated rat heart. Invest Radiol 28: 20–25
Almén T (1987) Effects of iodixanol, iopentol, iohexol and metrizoate on femoral blood flow after injection into the femoral artery of the dog. Acta Radiol (Suppl) 370: 69–72
Bolstad B, Borch KW, Grynne BH, Lundby B, Nossen JØ, Kloster YF, Kristoffersen DT, Andrew E (1991) Safety and tolerability of iodixanol. A dimeric, nonionic contrast medium: an emphasis on European clinical phases I and II. Invest Radiol 26: 5201–5204
Svaland MG, Haider T, Langseth MK, Andrew E, Hals PA (1992) Human pharmacokinetics of iodixanol. Invest Radiol 27:130–133
Kløw NE, Levorstad K, Berg KJ, Brodahl U, Endresen K, Kristoffersen DT, Laake B, Simonsen S, Tofte AJ, Lundby B (1993) Iodixanol in cardioangiography in patients with coronary artery disease. Tolerability, cardiac and renal effects. Acta Radiol 134: 72–77
Palmers Y, De Greef D, Grynne BH, Smits J, Put E (1993) A double-blind study comparing safety, tolerability and efficacy of iodixanol 320 mgI/ml and ioxaglate 320 mgI/ml in cerebral arteriography. Eur J Radiol 17: 203–209
Pugh ND, Sissons GR, Ruttley MS, Berg KJ, Nossen JØ, Eide H (1993) Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide. Clin Radiol 47: 96–99
Grynne BH, Nossen JØ, Bolstad B, Borch KW (1995) Main results of the first comparative clinical studies on Visipaque. Acta Radiol (in press)
Hine AL (1985) Contrast media osmolarity and plasma volume change. Acta Radiol Diagn 26: 753–756
Jakobsen JÅ, Nossen JØ, Morensen NP, Berg KJ (1993) Renal tubular effects of diuretics and X-ray contrast media. A comparative study of equimolar doses in healthy volunteers. Invest Radiol 28: 319–324
Lackner K, Köster O, Uexküll Vv, Broich H (1984) Nebenwirkungen nach hochdosierter Injektion nierengängiger Kontrastmittel. Fortschr R6ntgenstr 141: 447–452
Dundore RL, Silver PJ, Ezrin AM, Lee KC, Buchholz RA, van Aller G, Clas DM, Roth GM, Harnish PP, Bailey DM, Pagani D (1991) The effects of iodixanol and iopamidol on hemodynamic and cardiac electrophysiologic parameters in vitro and vivo. Invest Radiol 26: 715–721
Kløw NE, Mortensen E, Refsum H (1991) Left ventricular systolic and diastolic function during coronary arteriography before and after acute left ventricular failure in dogs. A comparison between iodixanol, iohexol and ioxaglate. Acta Radiol 32: 124–129
Gross-Fengels W, Beyer D, Fischbach R, Lanfermann H (1991) Akute Nebenwirkungen und Komplikationen der zentralvenösen DSA. Ergebnisse bei 2600 Untersuchungen. Med Klin 86: 561–565
Stevens JM, Al-Kutoubi A, Sheppick S, Klaveness AJ (1995) Visipaque (iodixanol) in intravenous cerebral digital subtraction angiography. Comparison with Omnipaque (iohexol). Eur Radiol (Suppl) 5: S391
Nakstad P (1983) Digital subtraction angiography of the carotid arteries. Acta Radiol (Suppl) 360: 89–93
Nossen JØ, Bach-Gansmo T, Kloster Y, Jørgensen NP (1993) Heat sensation in connection with intravenous injection od isotonic and low-osmolar X-ray contrast media and mannitol solutions. Eur Radiol 3: 46–48
Jørensen NP, Nossen JØ, Borch KW, Kristiansen AB, Kristoffersen DT, Lundby B, Theodorsen L (1992) Safety and tolerability of iodixanol in healthy volunteers with reference to two monomeric X-ray contrast media. Eur J Radiol 15: 252–257
Andersen PE, Bolstad B, Berg KJ, Justesen P, Thayssen P, Kloster YF (1993) Iodixanol and ioxaglate in cardioangiography: a double-blind randomized phase III study. Clin Radiol 48: 268–272
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fischbach, R., Landwehr, P., Lackner, K. et al. Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial. Eur. Radiol. 6, 9–13 (1996). https://doi.org/10.1007/BF00619943
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00619943